abstract |
Use of at least two direct-acting antiviral agents (DAAs) for the preparation of combined or separate compositions for the treatment of HCV in a patient infected with HCV genotype 1, wherein said at least two DAAs are PS1-7977 and GS-5885 (or an HCV NS5A inhibitor), wherein said treatment does not include the administration of interferon or the administration of ribavirin, and wherein said treatment lasts for 8, 9, 10, 11 or 12 weeks. |